BofA warns Fed risks policy mistake with early rate cuts
Florin Daniel P, a director at Pulmonx Corp (NASDAQ:LUNG), recently purchased 23,321 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The purchase comes as the stock trades near its 52-week low of $2.83, having declined over 53% in the past six months. The shares were acquired on June 5, 2025, at a weighted average price of $3.06 per share, totaling approximately $71,362. The purchase occurred at prices ranging from $3.01 to $3.09 per share. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 4.97 and holds more cash than debt on its balance sheet. Following this transaction, Daniel now holds 117,231 shares directly. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional key insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Pulmonx Corp reported its first-quarter 2025 earnings, revealing a smaller-than-expected loss per share of $0.36, surpassing the forecasted loss of $0.39. However, the company slightly missed revenue projections, posting $22.5 million against an expected $22.03 million. Despite this, Pulmonx reaffirmed its full-year revenue guidance between $96 million and $98 million, anticipating growth acceleration in the U.S. later in the year. Stifel analysts maintained their Buy rating for Pulmonx, with a price target of $16, citing expected sales growth in the latter half of 2025 due to strategic commercial initiatives. Meanwhile, Canaccord Genuity adjusted their price target for Pulmonx to $15 from $16 but upheld a Buy rating, expressing confidence in the company’s potential for long-term growth. Pulmonx’s management has indicated that U.S. sales growth will be bolstered by initiatives such as the rollout of LungTraX Connect/Detect and the addition of new Zephyr Valve therapy awareness specialists. The company also continues to expand internationally, with notable revenue growth in China and other markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.